These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 17074775)

  • 1. Haemodynamic and clinical effects of ularitide in decompensated heart failure.
    Mitrovic V; Seferovic PM; Simeunovic D; Ristic AD; Miric M; Moiseyev VS; Kobalava Z; Nitsche K; Forssmann WG; Lüss H; Meyer M
    Eur Heart J; 2006 Dec; 27(23):2823-32. PubMed ID: 17074775
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Renal effects of ularitide in patients with decompensated heart failure.
    Lüss H; Mitrovic V; Seferovic PM; Simeunovic D; Ristić AD; Moiseyev VS; Forssmann WG; Hamdy AM; Meyer M
    Am Heart J; 2008 Jun; 155(6):1012.e1-8. PubMed ID: 18513512
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of the renal natriuretic peptide urodilatin (ularitide) in patients with decompensated chronic heart failure: a double-blind, placebo-controlled, ascending-dose trial.
    Mitrovic V; Lüss H; Nitsche K; Forssmann K; Maronde E; Fricke K; Forssmann WG; Meyer M
    Am Heart J; 2005 Dec; 150(6):1239. PubMed ID: 16338265
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Therapeutic use of the natriuretic peptide ularitide in acute renal failure.
    Meyer M; Pfarr E; Schirmer G; Uberbacher HJ; Schöpe K; Böhm E; Flüge T; Mentz P; Scigalla P; Forssmann WG
    Ren Fail; 1999 Jan; 21(1):85-100. PubMed ID: 10048120
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hemodynamic effects of continuous urodilatin infusion: a dose-finding study.
    Dorner GT; Selenko N; Kral T; Schmetterer L; Eichler HG; Wolzt M
    Clin Pharmacol Ther; 1998 Sep; 64(3):322-30. PubMed ID: 9757156
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Concomitant treatment with urodilatin (ularitide) does not improve renal function in patients with acute renal failure after major abdominal surgery--a randomized controlled trial.
    Herbert MK; Ginzel S; Mühlschlegel S; Weis KH
    Wien Klin Wochenschr; 1999 Feb; 111(4):141-7. PubMed ID: 10192146
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Significance of prophylactic urodilatin (INN: ularitide) infusion for the prevention of acute renal failure in patients after heart transplantation.
    Brenner P; Meyer M; Reichenspurner H; Meiser B; Müller R; Mentz P; Schulz-Knappe P; Uberbacher HJ; Kreuzer E; Uberführ P
    Eur J Med Res; 1995 Dec; 1(3):137-43. PubMed ID: 9389675
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intravenous nesiritide, a natriuretic peptide, in the treatment of decompensated congestive heart failure. Nesiritide Study Group.
    Colucci WS; Elkayam U; Horton DP; Abraham WT; Bourge RC; Johnson AD; Wagoner LE; Givertz MM; Liang CS; Neibaur M; Haught WH; LeJemtel TH
    N Engl J Med; 2000 Jul; 343(4):246-53. PubMed ID: 10911006
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Randomized double-blind clinical studies of ularitide and other vasoactive substances in acute decompensated heart failure: a systematic review and meta-analysis.
    Mitrovic V; Forssmann WG; Schnitker J; Felix SB
    ESC Heart Fail; 2018 Dec; 5(6):1023-1034. PubMed ID: 30246939
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of Ularitide on Cardiovascular Mortality in Acute Heart Failure.
    Packer M; O'Connor C; McMurray JJV; Wittes J; Abraham WT; Anker SD; Dickstein K; Filippatos G; Holcomb R; Krum H; Maggioni AP; Mebazaa A; Peacock WF; Petrie MC; Ponikowski P; Ruschitzka F; van Veldhuisen DJ; Kowarski LS; Schactman M; Holzmeister J;
    N Engl J Med; 2017 May; 376(20):1956-1964. PubMed ID: 28402745
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effects of KW-3902, an adenosine A1-receptor antagonist,on diuresis and renal function in patients with acute decompensated heart failure and renal impairment or diuretic resistance.
    Givertz MM; Massie BM; Fields TK; Pearson LL; Dittrich HC;
    J Am Coll Cardiol; 2007 Oct; 50(16):1551-60. PubMed ID: 17936154
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Metabolism and action of urodilatin infusion in healthy volunteers.
    Carstens J; Jensen KT; Pedersen EB
    Clin Pharmacol Ther; 1998 Jul; 64(1):73-86. PubMed ID: 9695722
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Improved kidney function with intravenous prostaglandin E1 in patients with terminal heart failure].
    Wutte M; Hülsmann M; Berger R; Rödler S; Frey B; Stanek B; Pacher R
    Wien Klin Wochenschr; 1998 Jul; 110(13-14):473-8. PubMed ID: 9746960
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Urodilatin: a better natriuretic peptide?
    Vesely DL
    Curr Heart Fail Rep; 2007 Sep; 4(3):147-52. PubMed ID: 17883990
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cardio-renal effects of the A1 adenosine receptor antagonist SLV320 in patients with heart failure.
    Mitrovic V; Seferovic P; Dodic S; Krotin M; Neskovic A; Dickstein K; de Voogd H; Böcker C; Ziegler D; Godes M; Nakov R; Essers H; Verboom C; Hocher B
    Circ Heart Fail; 2009 Nov; 2(6):523-31. PubMed ID: 19919976
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cinaciguat (BAY 58-2667) improves cardiopulmonary hemodynamics in patients with acute decompensated heart failure.
    Lapp H; Mitrovic V; Franz N; Heuer H; Buerke M; Wolfertz J; Mueck W; Unger S; Wensing G; Frey R
    Circulation; 2009 Jun; 119(21):2781-8. PubMed ID: 19451356
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cinaciguat, a soluble guanylate cyclase activator, unloads the heart but also causes hypotension in acute decompensated heart failure.
    Erdmann E; Semigran MJ; Nieminen MS; Gheorghiade M; Agrawal R; Mitrovic V; Mebazaa A
    Eur Heart J; 2013 Jan; 34(1):57-67. PubMed ID: 22778174
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hemodynamic effects of alpha-human atrial natriuretic polypeptide on patients undergoing open-heart surgery.
    Ohki S; Ishikawa S; Ohtaki A; Takahashi T; Koyano T; Otani Y; Murakami J; Mohara J; Isa Y; Kunimoto F; Morishita Y
    J Cardiovasc Surg (Torino); 1999 Dec; 40(6):781-5. PubMed ID: 10776705
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rationale for and design of the TRUE-AHF trial: the effects of ularitide on the short-term clinical course and long-term mortality of patients with acute heart failure.
    Packer M; Holcomb R; Abraham WT; Anker S; Dickstein K; Filippatos G; Krum H; Maggioni AP; McMurray JJV; Mebazaa A; O'Connor C; Peacock F; Ponikowski P; Ruschitzka F; van Veldhuisen DJ; Holzmeister J;
    Eur J Heart Fail; 2017 May; 19(5):673-681. PubMed ID: 27862700
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The dual endothelin receptor antagonist tezosentan acutely improves hemodynamic parameters in patients with advanced heart failure.
    Schalcher C; Cotter G; Reisin L; Bertel O; Kobrin I; Guyene TT; Kiowski W
    Am Heart J; 2001 Aug; 142(2):340-9. PubMed ID: 11479476
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.